NeuroPace Inc

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation.

NPCE Nasdaq SEC CIK 1528287
Follow NeuroPace Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $23.1M −1.1% vs same quarter last year
Net income −$3.3M +5.7% vs same quarter last year
EPS, diluted −$0.10 +9.1% vs same quarter last year
Operating cash flow −$2.8M −42.1% vs same quarter last year
Revenue by quarter
$21.5M
$22.5M
$19.5M
$23.4M
$38.8M
$22.1M
$22.8M
$23.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$100M−$21.5M
FY24$79.9M−$27.1M
FY23$65.4M−$33M
FY22$45.5M−$47.1M
FY21$45.2M−$36.1M
FY20$41.1M−$24.3M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−150%−100%−50%0%50%100%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2577.2%−16.3%−21.5%
FY2473.9%−27.1%−34%
FY2373.6%−41.5%−50.4%
FY2271.4%−89.6%−103.4%
FY2174%−52.5%−79.9%
FY2073.6%−31.7%−59%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$11.3M
FY24−$18.3M
FY23−$19.9M
FY22−$37.5M
FY21−$25M
FY20−$21.7M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • NeuroPace
  • Healthcare median
−150%−100%−50%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNeuroPaceHealthcare median
FY25−21.5%−30.6%
FY24−34%−47%
FY23−50.4%−58%
FY22−103.4%−80.4%
FY21−79.9%−71.8%
FY20−59%−62.2%
FY19-−46.2%